Actelion Pharmaceuticals Ltd

Idorsia Pharmaceuticals Ltd

Corinna Grisostomi

Daniel Bur

Lubos Remen

Sylvia Richard-Bildstein

Olivier Corminboeuf

Sylvaine Cren

Xavier Leroy

Martin Bolli

Cornelia Zumbrunn

John Gatfield

Christoph Sager

Christoph Boss

Thomas Weller

Olivier Bezencon

Thierry Sifferlen

Oliver Nayler

Michel Therien

Daniel Dube

Magali Vercauteren

Richard Welford

Walter Fischli

Heinz Fretz

John Scheigetz

Christoph Binkert

Julien Pothier

Davide Pozzi

Dan McKay

Dwight MacDonald

Austin Chih-Yu Chen

Oliver Corminboeuf

Walter Fiśchli

Solange Meyer

David Powell

Sylvia Richard

The present invention relates to compounds of Formula (I) wherein Ar, R, R, R, and Rare as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

(2-acetamidyl)thio-beta-D-galactopyranoside derivatives

The present invention relates to compounds of Formula (I) wherein Ar, Ar, R, R, and Rare as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

(Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives

The present invention relates to compounds of Formula (I) wherein Ar, Rand Rare as described in the description, and A is 4,5-dihydroisoxazole-3,5-diyl, imidazolidin-4-one-1,3-diyl, oxazol-2-one-3,5-diyl and oxazolidine-2-one-3,5-diyl, 1,2,3-triazole-1,4-diyl, isoxazole-3,5-diyl, imidazole-1, 4-diyl, and isothiazole-3,5-diyl; and their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

Alpha-D-galactopyranoside derivatives

The present invention relates to compounds of Formula (I) wherein Ar, A, B, and Rare as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

Spiro derivatives of Alpha-D-galactopyranosides

The present invention relates to compounds of Formula (I) wherein X, Ar, Ar, L, n, m, and Rare as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

Hydroxyheterocycloalkane-carbamoyl derivatives

The present invention relates to compounds of Formula (I)

2-hydroxycycloalkane-1-carbamoyl

The present invention relates to compounds of Formula (I) wherein Ar, Ar, L, n, and Rare as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives

The present invention relates to compounds of the formula (I) wherein R, R, R, R, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.

Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase

The present invention relates to compounds of the formula (I) wherein R, R, R, R, R, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.

Tricyclic piperidine compounds

The invention relates to hydroxylated aminotriazole derivatives of formula (I), wherein Q, R, R, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds.

Hydroxylated aminotriazole derivatives as ALX receptor agonists

The invention relates to a method for preparing linear polymers having an amide end or having a star architecture comprising an amide core, by means of a ring opening using lactide and glycolide monomers or a lactide monomer ring in the presence of a catalyst, wherein the method includes the steps of: (i) reacting the excess monomer(s) with an initiator in a solvent, said initiator being selected from among an amine and an amino alcohol, given that the initiator has at least one primary or secondary amine function; (ii) adding a catalyst, said catalyst being a non-nucleophilic base and including at least one neutral sp2 nitrogen atom; and (iii) neutralizing the reaction mixture. Said novel method is particularly advantageous in that it can be easily monitored and enables better modulation of the polymers, and thus of the properties thereof, than the methods of the prior art. The invention also relates to novel polymers that are obtainable by means of said method.

Bridged Spiro[2.4]heptane ester derivatives

The invention relates to oxazolyl-methylether derivatives of formula (I), wherein R, R, R, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds.

Oxazolyl-methylether derivatives as ALX receptor agonists

The invention relates to oxazole and thiazole derivatives of formula (I), wherein A, E, X, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds. 

Oxazole and thiazole derivatives as ALX receptor agonists

The invention relates to fluorinated aminotriazole derivatives of formula (I), wherein A, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds. 

Fluorinated aminotriazole derivatives

The present invention relates to bridged spiro[2.4]heptane derivatives of formula (I), wherein W, Y, Z, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds as ALX receptor and/or FPRL2 agonists for the treatment of inflammatory and obstructive airways diseases. 

Growing community of inventors

Allschwil, Switzerland

Corinna Grisostomi